Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Vera Therapeutics (NASDAQ:VERA) shares surged 64% after positive late-stage trial results for atacicept in treating IgA ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

Company to host conference call and webcast on June 9, 2025, at 8:00 a.m. ETSAN FRANCISCO and VANCOUVER, British Columbia, ...

In Nature Communications the Korea Food Research Institute (KFRI) has released results on the growth regulation mechanisms of ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...